On November 28, 2022, Sean McLennan Treasurer, Senior Vice President, Finance and Corporate Controller of Molecular Templates, Inc. (Company), informed the Company of his intent to resign from his positions to pursue another opportunity. Mr. McLennan’s last day of employment with the Company is expected to be on January 5, 2023 (the “Effective Date”). Mr. McLennan’s resignation is not the result of any disagreement regarding the Company’s financial reporting or accounting policies, procedures, estimates or judgments.

The Company thanks Mr. McLennan for his service and wishes him well. On December 1, 2022, the board of directors of the Company appointed Jason Kim, the Company’s President and Chief Operating Officer as Treasurer and principal financial and accounting officer of the Company on an interim basis effective as of the Effective Date. The selection of Mr. Kim to perform the functions of interim principal financial and accounting officer and interim Chief Financial Officer and Treasurer was not pursuant to any arrangement or understanding with respect to any other person.

There are no family relationships between Mr. Kim and any director or executive officer of the Company, and there are no transactions between Mr. Kim and the Company that would be required to be reported under Item 404(a) of Regulation S-K. Mr. Kim, age 48, joined the Company in 2010 and served as the Company’s President and Chief Financial Officer until August 2017. Since August 2017, Mr. Kim has served as the President and Chief Operating Officer of the Company. Mr. Kim also served as the Company’s principal financial and principal accounting officer through the Company’s merger with Threshold Pharmaceuticals and the filing of its Quarterly Report on Form 10-Q on November 14, 2017.

Previously, Mr. Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals (acquired by Astellas) and ImClone Systems (acquired by Lilly). He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Mr. Kim holds a Master of Business Administration from The Wharton School and a Bachelor of Arts in Neuroscience from Wesleyan University.